human
parainfluenza
viru
type
import
caus
lower
respiratori
tract
ill
children
yet
licens
vaccin
antivir
drug
avail
evalu
safeti
toler
infect
immunogen
two
intranas
liveattenu
vaccin
design
b
cdnaderiv
chimera
bovin
evalu
adult
seroposit
children
seroneg
children
total
subject
particip
studi
b
highli
restrict
replic
adult
seroposit
children
readili
infect
seroneg
children
shed
mean
peak
viru
titer
vs
pfuml
respect
although
restrict
replic
seroneg
children
b
induc
significantli
higher
titer
hemagglutin
inhibit
hai
antibodi
taken
togeth
data
suggest
vaccin
prefer
candid
clinic
develop
human
parainfluenza
viru
type
account
least
pediatr
hospit
annual
unit
state
import
caus
acut
lower
respiratori
ill
alri
infant
young
children
worldwid
like
respiratori
syncyti
viru
rsv
caus
bronchiol
viral
pneumonia
apnea
infant
associ
wheez
episod
older
children
asthma
although
precis
estim
exist
outpati
burden
like
substanti
sinc
number
emerg
room
outpati
visit
ill
may
exceed
hospit
sinc
approxim
twothird
hospit
occur
first
year
life
develop
vaccin
capabl
induc
protect
immun
infanc
urgent
need
liveattenu
intranasallyadminist
offer
sever
potenti
advantag
vaccin
infant
includ
eas
administr
reduct
likelihood
interfer
mani
childhood
vaccin
given
parenter
first
year
life
lack
restrict
vaccin
viru
replic
presenc
matern
serum
antibodi
present
earli
infanc
induct
local
immun
sinc
immunogen
vaccin
administ
first
month
life
typic
less
observ
older
children
one
dose
vaccin
would
like
need
induc
last
protect
immun
infant
children
serum
antibodi
respons
surfac
antigen
name
hemagglutininneuraminidas
hn
fusion
f
glycoprotein
recogn
correl
protect
immun
role
aspect
host
immun
protect
respons
well
understood
particularli
pediatr
popul
two
approach
use
gener
vaccin
clinic
develop
first
wildtyp
wt
attenu
serial
passag
low
temperatur
yield
shown
welltoler
infecti
immunogen
phenotyp
stabl
children
young
one
month
age
recent
toler
level
attenu
immunogen
cdnaderiv
recombin
version
design
shown
compar
previous
observ
biologicallyderiv
vaccin
karron
ra
et
al
press
use
cdnaderiv
viru
advantag
short
wellcharacter
passag
histori
well
abil
readili
regener
modifi
viru
need
anoth
approach
vaccin
develop
base
relat
anim
viru
bovin
parainfluenza
type
evolv
bovin
restrict
replic
human
ie
exhibit
hostrang
phenotyp
shown
welltoler
attenu
adult
children
infant
young
one
month
age
howev
crossneutr
studi
demonstr
hn
f
protein
antigen
relat
hn
f
antibodi
respons
children
administ
suboptim
reason
cdnaderiv
chimer
virus
develop
contain
hn
f
gene
backbon
contain
one
gene
purpos
strategi
combin
antigen
specif
hn
f
glycoprotein
host
rang
restrict
previou
studi
nonhuman
primat
demonstr
gene
independ
contribut
hostrang
attenu
phenotyp
suggest
chimer
humanbovin
vaccin
could
develop
contain
either
singl
gene
substitut
multipl
attenu
gene
present
studi
evalu
one
exampl
type
chimer
humanbovin
vaccin
clinic
trial
b
nucleocapsid
n
gene
replac
counterpart
rest
genom
contrast
consist
hn
f
gene
replac
counterpart
previou
studi
b
found
attenu
nonhuman
primat
induc
higher
titer
antibodi
hn
induc
report
phase
evalu
vaccin
adult
children
infant
young
month
age
gener
recombin
b
cdna
encod
genom
js
strain
modifi
replac
nucleoprotein
n
open
read
frame
orf
n
orf
kansa
strain
cdna
use
deriv
infecti
viru
previous
describ
vaccin
seed
viru
clinic
trial
materi
ctm
manufactur
qualifi
vero
cell
novavax
inc
rockvil
md
deriv
entir
plasmid
cdna
qualifi
vero
cell
nation
institut
health
nih
ctm
manufactur
qualifi
vero
cell
charl
river
laboratori
malvern
pa
b
ctm
suppli
clinic
site
frozen
concentr
mean
infect
titer
tissuecultureinfectiousdos
tcid
per
ml
respect
ctm
store
dilut
dose
onsit
use
leibovitz
medium
medium
also
use
placebo
trial
conduct
center
immun
research
john
hopkin
bloomberg
school
public
health
enrol
b
trial
complet
april
octob
enrol
trial
complet
juli
decemb
clinicaltrialsgov
identifi
trial
b
trial
done
earlier
identifi
vaccin
evalu
sequenti
adult
screen
serostatu
prove
seroposit
ii
seroposit
children
age
month
iii
seroneg
children
age
month
studi
adult
conduct
openlabel
trial
subject
receiv
vaccin
studi
children
conduct
random
doubleblind
placebocontrol
trial
subject
random
receiv
vaccin
placebo
random
perform
block
vaccine
placebo
recipi
permit
unblind
analysi
advers
event
throughout
studi
done
group
subject
complet
initi
followup
period
approxim
day
seroposit
children
approxim
day
seroneg
children
vaccin
placebo
administ
volum
ml
nose
drop
approxim
ml
per
nostril
studi
design
evalu
singl
dose
level
vaccin
adult
seroposit
children
evalu
lower
dose
seroneg
children
addit
studi
conting
subsequ
increas
dose
seroneg
children
infect
vaccin
viru
insuffici
initi
lower
dose
insuffici
infect
prespecifi
seroneg
children
infect
infect
defin
shed
vaccin
viru
andor
rise
serum
antibodi
titer
b
dose
evalu
adult
seroposit
children
tcid
dose
evalu
seroneg
children
tcid
tcid
dose
evalu
adult
seroposit
children
tcid
dose
evalu
seroneg
children
tcid
higher
dose
util
base
upon
infect
b
viru
describ
result
section
written
inform
consent
obtain
studi
particip
adult
parent
guardian
studi
particip
children
prior
enrol
studi
conduct
accord
principl
declar
helsinki
standard
good
clinic
practic
defin
intern
confer
harmon
studi
perform
niaidheld
investig
new
drug
applic
bbind
review
us
food
drug
administr
clinic
protocol
consent
form
investig
brochur
develop
cir
niaid
investig
review
approv
western
institut
review
board
wirb
niaid
regulatori
complianc
human
subject
protect
branch
rchspb
clinic
data
review
cir
niaid
investig
safeti
monitor
b
data
safeti
monitor
board
niaid
divis
clinic
research
adult
seroposit
children
enrol
trial
clinic
assess
nasal
wash
perform
studi
day
day
vaccin
nasal
wash
perform
prior
inocul
day
follow
inocul
follow
day
ill
data
advers
event
reactogen
event
collect
day
addit
physic
examin
perform
nasal
wash
obtain
event
lower
respiratori
tract
ill
lri
lri
defin
seriou
advers
event
sae
regardless
sever
requir
fda
serum
alanin
aminotransferas
alt
measur
adult
seroposit
children
inocul
day
inocul
b
seroneg
children
clinic
assess
nasal
wash
perform
studi
day
day
day
part
studi
addit
clinic
assess
nasal
wash
perform
day
followup
phone
call
conduct
approxim
month
vaccin
determin
whether
sae
occur
acut
observ
period
follow
last
schedul
nasal
wash
ill
data
obtain
seroneg
children
day
physic
examin
perform
addit
nasal
wash
obtain
event
lri
titer
vaccin
viru
nasal
wash
specimen
determin
describ
fever
upper
respiratori
tract
ill
uri
rhinorrhea
pharyng
cough
lri
otiti
media
defin
previous
describ
ill
occur
nasal
wash
test
adventiti
agent
viral
cultur
b
studi
rrtpcr
fasttrack
diagnost
luxembourg
studi
sera
obtain
measur
antibodi
prior
inocul
approxim
month
inocul
adult
seroposit
children
approxim
month
inocul
seroneg
children
nasal
wash
perform
use
nasal
bulb
syring
ml
lactat
ringer
solut
nasal
wash
snap
frozen
site
store
aliquot
nasal
wash
rapidli
thaw
inocul
onto
cell
incub
primari
viru
isol
specimen
show
cytopath
effect
evid
infect
hemadsorpt
second
aliquot
titer
hemadsorpt
plaqu
assay
agar
overlay
cell
titer
vaccin
viru
express
number
plaqueform
unit
pfu
per
ml
nasal
wash
fluid
lower
limit
detect
log
pfuml
differenti
rna
extract
viru
isol
use
viral
rna
mini
kit
qiagen
valencia
ca
cdna
gener
use
superscript
first
strand
kit
invitrogen
carlsbad
ca
cdna
amplifi
virusspecif
primer
use
clontech
advantag
pcr
kit
clontech
mountain
view
ca
sera
subject
test
antibodi
use
strain
assay
viru
hemagglutinationinhibit
hai
antibodi
test
start
serum
dilut
dilut
increment
endpoint
titrat
infect
vaccin
viru
defin
either
isol
vaccin
viru
rise
antibodi
titer
measur
serum
hai
mean
peak
titer
vaccin
viru
shed
log
pfuml
calcul
infect
vaccine
hai
reciproc
titer
transform
log
valu
calcul
mean
log
titer
student
test
use
compar
hai
titer
group
rate
ill
among
vaccine
placebo
recipi
compar
twotail
fisher
exact
test
shown
tabl
figur
subject
enrol
studi
vaccin
administ
adult
adult
total
vaccin
next
evalu
cohort
seroposit
children
receiv
vaccin
receiv
placebo
seroposit
children
total
b
vaccin
subsequ
evalu
cohort
seroneg
children
receiv
tcid
vaccin
receiv
tcid
vaccin
receiv
placebo
rb
vaccin
evalu
cohort
seroneg
children
receiv
tcid
vaccin
receiv
placebo
total
seroneg
children
particip
trial
adult
seroposit
children
b
well
toler
subject
highli
restrict
replic
tabl
vaccinationrel
sae
occur
studi
b
adult
seroposit
children
evid
infect
vaccin
viru
tabl
subject
shed
vaccin
viru
asymptomat
includ
one
seroposit
child
receiv
shed
vaccin
viru
studi
day
rel
high
peak
titer
tcid
ml
nasal
wash
fluid
replic
vaccin
virus
highli
restrict
subject
ill
fever
rhinorrhea
cough
andor
otiti
media
occur
subject
infect
vaccin
virus
one
individu
shed
wt
human
parainfluenza
viru
type
alt
elev
observ
subject
antibodi
respons
measur
rise
serum
hai
titer
detect
recipi
b
vaccin
vaccin
seroposit
child
rel
high
level
vaccin
viru
shed
note
develop
antibodi
respons
tabl
taken
togeth
data
suggest
vaccin
poorli
infecti
immunogen
popul
b
vaccin
infect
seroneg
children
dose
level
tcid
specifi
protocol
increas
dose
vaccin
welltoler
infect
tcid
dose
level
next
evalu
addit
group
seroneg
children
children
receiv
higher
dose
infect
base
find
viru
administ
initi
dose
tcid
infect
seroneg
children
tabl
vaccin
viru
replic
compar
group
seroneg
children
receiv
tcid
either
vaccin
mean
peak
titer
vaccin
viru
nasal
wash
fluid
nearli
greater
b
vaccine
vaccine
vs
pfuml
differ
statist
signific
howev
mean
durat
vaccin
viru
shed
significantli
greater
seroneg
recipi
b
seroneg
recipi
vs
day
tabl
figur
upper
respiratori
tract
febril
ill
frequent
observ
vaccin
placebo
recipi
rate
ill
similar
group
tabl
one
seroneg
recipi
met
protocol
definit
lri
rhonchi
heard
auscult
studi
day
child
afebril
show
sign
symptom
lri
lri
vaccinationrel
sae
report
child
shed
vaccin
viru
studi
day
vaccin
viru
detect
nasal
wash
specimen
subsequ
day
particular
time
lri
day
howev
human
metapneumoviru
bocaviru
coronaviru
detect
nasal
wash
obtain
time
suggest
communityacquir
infect
like
caus
lri
tabl
detect
nasal
wash
obtain
two
placebo
recipi
trial
viru
isol
nasal
wash
specimen
obtain
one
placebo
recipi
studi
day
second
placebo
recipi
studi
day
sequenc
confirm
wt
isol
singl
dose
tcid
either
vaccin
induc
serum
antibodi
respons
nearli
seroneg
vaccine
b
recipi
recipi
rise
hai
antibodi
titer
follow
vaccin
tabl
note
mean
reciproc
log
serum
hai
antibodi
titer
recipi
singl
dose
tcid
significantli
higher
vaccine
b
vaccine
vs
tabl
signific
differ
prevaccin
titer
observ
two
group
use
antigen
relat
anim
virus
immun
human
pathogen
led
erad
smallpox
recent
develop
liveattenu
bovinehuman
reassort
rotaviru
vaccin
other
previous
evalu
liveattenu
vaccin
found
welltoler
highli
infecti
seroneg
children
infant
young
month
age
major
children
month
age
experiment
vaccin
also
elicit
serum
hai
antibodi
respons
hn
glycoprotein
major
viral
protect
antigen
howev
children
develop
high
titer
antibodi
hn
result
consist
crossneutr
studi
demonstr
antigen
related
hn
f
suggest
inclus
hn
f
glycoprotein
would
import
induct
antibodi
protect
antigen
studi
describ
evalu
two
experiment
chimer
bovinehuman
vaccin
vaccin
contain
hn
f
glycoprotein
b
singl
gene
substitut
recombin
contribut
n
gene
encod
protein
wherea
contain
intern
gene
f
hn
gene
encod
protein
b
previous
evalu
rhesu
monkey
replic
chimer
virus
nonhuman
primat
compar
replic
upper
respiratori
tract
level
intermedi
parent
wt
strain
wt
highli
restrict
lower
respiratori
tract
similar
interestingli
howev
replic
two
experiment
vaccin
differ
seroneg
children
studi
mean
peak
titer
viru
detect
nasal
wash
fluid
greater
b
vs
pfuml
mean
durat
shed
significantli
greater
b
vs
day
dose
tcid
b
slightli
less
restrict
replic
seroneg
children
parent
mean
peak
titer
tcid
mean
durat
shed
day
replic
b
restrict
compar
previous
observ
children
natur
infect
wt
studi
underscor
need
care
stepwis
evalu
suscept
pediatr
popul
uncov
subtl
differ
may
appar
virus
evalu
nonhuman
primat
despit
restrict
replic
vaccin
induc
significantli
higher
titer
hai
antibodi
b
vaccin
vs
reciproc
mean
log
titer
reason
appar
differ
unclear
one
potenti
explan
observ
might
accessori
p
gene
product
encod
rb
vaccin
less
abl
inhibit
human
interferon
induct
signal
p
gene
product
encod
b
vaccin
greater
interferon
product
signal
respons
vaccin
might
adjuv
effect
result
stronger
antibodi
respons
note
bovin
infect
bovin
rsv
mutant
differ
abil
control
host
interferon
respons
case
combin
greater
restrict
replic
increas
antibodi
respons
make
vaccin
promis
candid
b
vaccin
titer
antibodi
achiev
seroneg
children
singl
dose
vaccin
slightli
lower
measur
seroposit
children
presum
experienc
prior
infect
wt
tabl
sinc
one
dose
vaccin
would
like
administ
possibl
antibodi
titer
compar
infect
wt
might
achiev
follow
complet
vaccin
seri
toler
vaccin
difficult
assess
complet
small
phase
clinic
trial
importantli
lri
andor
sae
associ
vaccin
viru
shed
observ
fever
upper
respiratori
ill
frequent
detect
vaccine
placebo
recipi
varieti
adventiti
viral
agent
isol
sever
subject
type
ill
often
occur
infant
preschool
confound
assess
reactogen
liveattenu
respiratori
viru
vaccin
particular
assess
causal
relationship
vaccin
administr
mild
ill
rhinorrhea
requir
studi
larger
number
children
exampl
associ
liveattenu
influenza
vaccin
flumist
mild
upper
respiratori
symptom
appar
largescal
studi
complet
vaccin
undergo
clinic
develop
addit
inform
regard
safeti
reactogen
vaccin
need
obtain
summari
shown
two
chimer
bovinehuman
virus
restrict
replic
seroneg
children
two
vaccin
appear
restrict
replic
immunogen
make
prefer
candid
clinic
develop
current
liveattenu
vaccin
recombin
version
shown
highli
attenu
infecti
immunogen
phase
ii
clinic
trial
infant
children
repres
potenti
addit
liveattenu
investig
vaccin
could
evalu
phase
iiiii
studi
altern
could
use
express
surfac
glycoprotein
relat
paramyxovirus
import
pediatr
pathogen
rsv
human
metapneumoviru
evalu
similar
chimer
vaccin
viru
express
rsv
f
protein
ad
gene
current
progress
enrol
adult
seroposit
seroneg
children
phase
clinic
trial
b
vaccin
describ
section
adult
enrol
openlabel
trial
children
enrol
placebocontrol
trial
vaccin
studi
perform
sequenti
adult
seroposit
children
seroneg
children
doseescal
studi
perform
seroneg
cohort
children
receiv
b
vaccin
insuffici
infecti
dose
subject
withdrew
studi
addit
detail
provid
text
quantit
vaccin
viru
shed
nasal
wash
seroneg
recipi
tcid
either
b
mean
standard
deviat
log
titer
shown
shed
vaccin
viru
log
pfuml
repres
limit
detect
assay
karron
tabl
serum
antibodi
respons
adult
children
follow
intranas
administr
b
placebo
c
placebo
recipi
studi
singl
placebo
recipi
experienc
rise
serum
hai
titer
particip
inocul
septemb
may
infect
wildtyp
collect
postinocul
serum
specimen
novemb
e
two
placebo
recipi
experienc
rise
serum
hai
titer
wt
detect
nasal
wash
specimen
obtain
children
